Compare Apple Inc (AAPL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Apple Inc trades at $314.28 (market cap $4.56T), while Vertex Pharmaceuticals Incorporated trades at $506.25 (market cap $132.55B). The key difference: Apple Inc is far larger — about 34.4× Vertex Pharmaceuticals Incorporated's market cap, and Apple Inc pays a 0.35% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AAPL | VRTX | |
|---|---|---|
Market Cap | $4.56T | $132.55B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $529.59 |
52-Week Low | $202.38 | $366.54 |
Enterprise Value | $4.58T | $127.29B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $314.13, up 0.47% today, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $416.16B and net income of $112.01B, beating earnings estimates in recent quarters. Analyst consensus is bullish with a $329.62 price target, though valuation ratios like P/E of 37.61 and P/B of 42.85 suggest premium pricing. Recent news highlights AI potential via a partnership with Alphabet's Gemini and ongoing retail adjustments.
Outlook remains positive driven by earnings growth and AI integration, but risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny. The stock offers stability with consistent cash flow and dividend payments, yet investors should weigh premium multiples against growth sustainability in a challenging macro environment.
Vertex Pharmaceuticals (VRTX) trades at $522.25, down 1.1% on the day but remains near its all-time high. The stock shows strong fundamentals with 35.5% net income margins and robust cash flow generation. Recent developments include a $10 billion acquisition of Crinetics Pharmaceuticals and FDA approval for expanded use of its gene therapy CASGEVY in younger patients. Technical indicators show bullish moving averages but overbought oscillators with RSI readings above 89.
The outlook remains positive with 84% analyst buy ratings and a consensus price target of $522. Key catalysts include the Crinetics acquisition's $5 billion peak sales potential and continued gene therapy expansion. Risks include integration challenges from the major acquisition and potential regulatory hurdles. The stock trades at premium valuations (P/E 31.4) but justifies this with strong profitability and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
